Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study
Introduction The method of therapy administration and injection device characteristics have been documented to influence perceptions and preference of treatment among patients with type 2 diabetes (T2D). We aimed to assess the metabolic effectiveness and patient-reported satisfaction of once-weekly...
Gespeichert in:
| Veröffentlicht in: | Advances in therapy 2022-04, Vol.39 (4), p.1582-1595 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1595 |
|---|---|
| container_issue | 4 |
| container_start_page | 1582 |
| container_title | Advances in therapy |
| container_volume | 39 |
| creator | Al Hayek, Ayman A. Al Dawish, Mohamed A. |
| description | Introduction
The method of therapy administration and injection device characteristics have been documented to influence perceptions and preference of treatment among patients with type 2 diabetes (T2D). We aimed to assess the metabolic effectiveness and patient-reported satisfaction of once-weekly semaglutide compared to liraglutide in suboptimally controlled patients with T2D.
Methods
We conducted this single-center cohort study at diabetes center clinics at a tertiary care hospital between February 2021 and August 2021. We included suboptimally controlled patients with T2D who had been treated with liraglutide for at least 3 months at baseline, then shifted to once-weekly semaglutide and followed up for the same period. Ambulatory glucose profile (AGP) metrics [i.e., mean glucose level, glycemic variability (GV), time above range (TAR), and time in range (TIR)] for baseline and follow-up were compared. To assess the satisfaction with shifting, we used the valid Arabic version of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) while the injection device preference was assessed using the Diabetes Injection Device Preference Questionnaire (DID-PQ).
Results
We included 52 patients (25 male and 27 female), with a mean age of 48 (± 6) years and a mean diabetes mellitus duration of 7.27 (± 3.79) years. We observed a significantly decreased mean HbA1c level following semaglutide treatment (7.79% at study end vs. 8.07% at baseline,
p
|
| doi_str_mv | 10.1007/s12325-022-02053-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2626009300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2626009300</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-f80daee9cc0b28650cb55ab3caa68d19c9ec231c6586daed78317524cc27f1163</originalsourceid><addsrcrecordid>eNp9kU1O5DAQhS3ECBqYC7BAXrIx4592fti1mgZGQmJEg5id5TgVMCROiB1QDsKes3CycdPAchalsuzvvVL5IbTP6BGjNP3lGRdcEsp5LCoFoRtowrJEklh8E01oOmWEi-zvNtrx_oFGKpXZFtoWkrE84XyCXhfPuh50sK3DbYX_xBO4QK6ga_sAJV7GC19p8wFoV-J5bZ01usaLqordjCvZpTNAbgEe6xEvodF39RBsCdi6L0ePX2y4x9djB-9vHJ9YXUAAf4xnDs-awvoO4oxnwMswlOMe-lHp2sPPz76Lbk4X1_NzcnF59ns-uyBGTNNAqoyWGiA3hhY87kxNIaUuhNE6yUqWmxwMF8wkMksiWKaZYKnkU2N4WjGWiF10uPbt-vZpAB9UY72ButYO2sErnvCE0lxQGlG-Rk3fet9DpbreNrofFaNqFYdax6FiHOojDrUSHXz6D0UD5bfk6_8jINaAj0_uDnr10A69izv_z_Yfh_6YUw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2626009300</pqid></control><display><type>article</type><title>Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Al Hayek, Ayman A. ; Al Dawish, Mohamed A.</creator><creatorcontrib>Al Hayek, Ayman A. ; Al Dawish, Mohamed A.</creatorcontrib><description>Introduction
The method of therapy administration and injection device characteristics have been documented to influence perceptions and preference of treatment among patients with type 2 diabetes (T2D). We aimed to assess the metabolic effectiveness and patient-reported satisfaction of once-weekly semaglutide compared to liraglutide in suboptimally controlled patients with T2D.
Methods
We conducted this single-center cohort study at diabetes center clinics at a tertiary care hospital between February 2021 and August 2021. We included suboptimally controlled patients with T2D who had been treated with liraglutide for at least 3 months at baseline, then shifted to once-weekly semaglutide and followed up for the same period. Ambulatory glucose profile (AGP) metrics [i.e., mean glucose level, glycemic variability (GV), time above range (TAR), and time in range (TIR)] for baseline and follow-up were compared. To assess the satisfaction with shifting, we used the valid Arabic version of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) while the injection device preference was assessed using the Diabetes Injection Device Preference Questionnaire (DID-PQ).
Results
We included 52 patients (25 male and 27 female), with a mean age of 48 (± 6) years and a mean diabetes mellitus duration of 7.27 (± 3.79) years. We observed a significantly decreased mean HbA1c level following semaglutide treatment (7.79% at study end vs. 8.07% at baseline,
p
< 0.001) and body weight (84.64 ± 7.68 vs. 87.15 ± 8.011,
p
< 0.001). Compared to the glucometrics data at baseline, we observed a significantly improved mean average glucose, GV, TAR, and TIR (
p
< 0.001). Data from the DTSQs and DTSQc questionnaires showed a high level of patient-reported satisfaction after shifting to semaglutide treatment. All patients preferred/strongly preferred once-weekly semaglutide over liraglutide in most DID-PQ questionnaire domains.
Conclusions
Switching from once-daily liraglutide to once-weekly semaglutide led to improvements in both clinical measures of glycemic control and patient-reported satisfaction.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-022-02053-0</identifier><identifier>PMID: 35119622</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Blood Glucose ; Cardiology ; Cohort Studies ; Diabetes Mellitus, Type 2 - drug therapy ; Endocrinology ; Female ; Glucagon-Like Peptides - therapeutic use ; Glycated Hemoglobin A - analysis ; Humans ; Hypoglycemic Agents ; Internal Medicine ; Liraglutide - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Research ; Patient Reported Outcome Measures ; Patient Satisfaction ; Personal Satisfaction ; Pharmacology/Toxicology ; Rheumatology ; Treatment Outcome</subject><ispartof>Advances in therapy, 2022-04, Vol.39 (4), p.1582-1595</ispartof><rights>The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-f80daee9cc0b28650cb55ab3caa68d19c9ec231c6586daed78317524cc27f1163</citedby><cites>FETCH-LOGICAL-c347t-f80daee9cc0b28650cb55ab3caa68d19c9ec231c6586daed78317524cc27f1163</cites><orcidid>0000-0002-3483-3196</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12325-022-02053-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12325-022-02053-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35119622$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al Hayek, Ayman A.</creatorcontrib><creatorcontrib>Al Dawish, Mohamed A.</creatorcontrib><title>Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study</title><title>Advances in therapy</title><addtitle>Adv Ther</addtitle><addtitle>Adv Ther</addtitle><description>Introduction
The method of therapy administration and injection device characteristics have been documented to influence perceptions and preference of treatment among patients with type 2 diabetes (T2D). We aimed to assess the metabolic effectiveness and patient-reported satisfaction of once-weekly semaglutide compared to liraglutide in suboptimally controlled patients with T2D.
Methods
We conducted this single-center cohort study at diabetes center clinics at a tertiary care hospital between February 2021 and August 2021. We included suboptimally controlled patients with T2D who had been treated with liraglutide for at least 3 months at baseline, then shifted to once-weekly semaglutide and followed up for the same period. Ambulatory glucose profile (AGP) metrics [i.e., mean glucose level, glycemic variability (GV), time above range (TAR), and time in range (TIR)] for baseline and follow-up were compared. To assess the satisfaction with shifting, we used the valid Arabic version of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) while the injection device preference was assessed using the Diabetes Injection Device Preference Questionnaire (DID-PQ).
Results
We included 52 patients (25 male and 27 female), with a mean age of 48 (± 6) years and a mean diabetes mellitus duration of 7.27 (± 3.79) years. We observed a significantly decreased mean HbA1c level following semaglutide treatment (7.79% at study end vs. 8.07% at baseline,
p
< 0.001) and body weight (84.64 ± 7.68 vs. 87.15 ± 8.011,
p
< 0.001). Compared to the glucometrics data at baseline, we observed a significantly improved mean average glucose, GV, TAR, and TIR (
p
< 0.001). Data from the DTSQs and DTSQc questionnaires showed a high level of patient-reported satisfaction after shifting to semaglutide treatment. All patients preferred/strongly preferred once-weekly semaglutide over liraglutide in most DID-PQ questionnaire domains.
Conclusions
Switching from once-daily liraglutide to once-weekly semaglutide led to improvements in both clinical measures of glycemic control and patient-reported satisfaction.</description><subject>Blood Glucose</subject><subject>Cardiology</subject><subject>Cohort Studies</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Glucagon-Like Peptides - therapeutic use</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Humans</subject><subject>Hypoglycemic Agents</subject><subject>Internal Medicine</subject><subject>Liraglutide - therapeutic use</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Research</subject><subject>Patient Reported Outcome Measures</subject><subject>Patient Satisfaction</subject><subject>Personal Satisfaction</subject><subject>Pharmacology/Toxicology</subject><subject>Rheumatology</subject><subject>Treatment Outcome</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1O5DAQhS3ECBqYC7BAXrIx4592fti1mgZGQmJEg5id5TgVMCROiB1QDsKes3CycdPAchalsuzvvVL5IbTP6BGjNP3lGRdcEsp5LCoFoRtowrJEklh8E01oOmWEi-zvNtrx_oFGKpXZFtoWkrE84XyCXhfPuh50sK3DbYX_xBO4QK6ga_sAJV7GC19p8wFoV-J5bZ01usaLqordjCvZpTNAbgEe6xEvodF39RBsCdi6L0ePX2y4x9djB-9vHJ9YXUAAf4xnDs-awvoO4oxnwMswlOMe-lHp2sPPz76Lbk4X1_NzcnF59ns-uyBGTNNAqoyWGiA3hhY87kxNIaUuhNE6yUqWmxwMF8wkMksiWKaZYKnkU2N4WjGWiF10uPbt-vZpAB9UY72ButYO2sErnvCE0lxQGlG-Rk3fet9DpbreNrofFaNqFYdax6FiHOojDrUSHXz6D0UD5bfk6_8jINaAj0_uDnr10A69izv_z_Yfh_6YUw</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Al Hayek, Ayman A.</creator><creator>Al Dawish, Mohamed A.</creator><general>Springer Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3483-3196</orcidid></search><sort><creationdate>20220401</creationdate><title>Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study</title><author>Al Hayek, Ayman A. ; Al Dawish, Mohamed A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-f80daee9cc0b28650cb55ab3caa68d19c9ec231c6586daed78317524cc27f1163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Blood Glucose</topic><topic>Cardiology</topic><topic>Cohort Studies</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Glucagon-Like Peptides - therapeutic use</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Humans</topic><topic>Hypoglycemic Agents</topic><topic>Internal Medicine</topic><topic>Liraglutide - therapeutic use</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Research</topic><topic>Patient Reported Outcome Measures</topic><topic>Patient Satisfaction</topic><topic>Personal Satisfaction</topic><topic>Pharmacology/Toxicology</topic><topic>Rheumatology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al Hayek, Ayman A.</creatorcontrib><creatorcontrib>Al Dawish, Mohamed A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al Hayek, Ayman A.</au><au>Al Dawish, Mohamed A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Ther</stitle><addtitle>Adv Ther</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>39</volume><issue>4</issue><spage>1582</spage><epage>1595</epage><pages>1582-1595</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Introduction
The method of therapy administration and injection device characteristics have been documented to influence perceptions and preference of treatment among patients with type 2 diabetes (T2D). We aimed to assess the metabolic effectiveness and patient-reported satisfaction of once-weekly semaglutide compared to liraglutide in suboptimally controlled patients with T2D.
Methods
We conducted this single-center cohort study at diabetes center clinics at a tertiary care hospital between February 2021 and August 2021. We included suboptimally controlled patients with T2D who had been treated with liraglutide for at least 3 months at baseline, then shifted to once-weekly semaglutide and followed up for the same period. Ambulatory glucose profile (AGP) metrics [i.e., mean glucose level, glycemic variability (GV), time above range (TAR), and time in range (TIR)] for baseline and follow-up were compared. To assess the satisfaction with shifting, we used the valid Arabic version of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) while the injection device preference was assessed using the Diabetes Injection Device Preference Questionnaire (DID-PQ).
Results
We included 52 patients (25 male and 27 female), with a mean age of 48 (± 6) years and a mean diabetes mellitus duration of 7.27 (± 3.79) years. We observed a significantly decreased mean HbA1c level following semaglutide treatment (7.79% at study end vs. 8.07% at baseline,
p
< 0.001) and body weight (84.64 ± 7.68 vs. 87.15 ± 8.011,
p
< 0.001). Compared to the glucometrics data at baseline, we observed a significantly improved mean average glucose, GV, TAR, and TIR (
p
< 0.001). Data from the DTSQs and DTSQc questionnaires showed a high level of patient-reported satisfaction after shifting to semaglutide treatment. All patients preferred/strongly preferred once-weekly semaglutide over liraglutide in most DID-PQ questionnaire domains.
Conclusions
Switching from once-daily liraglutide to once-weekly semaglutide led to improvements in both clinical measures of glycemic control and patient-reported satisfaction.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>35119622</pmid><doi>10.1007/s12325-022-02053-0</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-3483-3196</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0741-238X |
| ispartof | Advances in therapy, 2022-04, Vol.39 (4), p.1582-1595 |
| issn | 0741-238X 1865-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2626009300 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Blood Glucose Cardiology Cohort Studies Diabetes Mellitus, Type 2 - drug therapy Endocrinology Female Glucagon-Like Peptides - therapeutic use Glycated Hemoglobin A - analysis Humans Hypoglycemic Agents Internal Medicine Liraglutide - therapeutic use Male Medicine Medicine & Public Health Middle Aged Oncology Original Research Patient Reported Outcome Measures Patient Satisfaction Personal Satisfaction Pharmacology/Toxicology Rheumatology Treatment Outcome |
| title | Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T12%3A30%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Patient-Reported%20Satisfaction%20and%20Clinical%20Efficacy%20of%20Once-Weekly%20Semaglutide%20in%20Patients%20with%20Type%C2%A02%20Diabetes:%20An%20Ambispective%20Study&rft.jtitle=Advances%20in%20therapy&rft.au=Al%20Hayek,%20Ayman%20A.&rft.date=2022-04-01&rft.volume=39&rft.issue=4&rft.spage=1582&rft.epage=1595&rft.pages=1582-1595&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-022-02053-0&rft_dat=%3Cproquest_cross%3E2626009300%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2626009300&rft_id=info:pmid/35119622&rfr_iscdi=true |